“This could be ah, an immunotherapy the basis of a therapeutic for ah for cancer. So we implemented for the first time the idea of evolving vaccinia or creating new versions of Vaccinia that would excel at being able to replicate within a tumor that became the basis of ah the. Lead technology and ah Pfizer acquired that so they could further develop it for for clinical application.”